Heather Kimmel

Dr. Heather Kimmel

National Institutes of Health
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2016 in Tobacco Control
Verified
Journal Article
Open access
PDF file
AHAndrew Hyland
Andrew Hyland
BABridget K Ambrose
Bridget K Ambrose
KCKevin Conway
Kevin Conway
NBNicolette Borek
Nicolette Borek
ELElizabeth Lambert
Elizabeth Lambert
WCWilson M Compton
Wilson M Compton
Background This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration's (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat. Methods The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study's design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use. Conclusions The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA's regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation's burden of tobacco-related death and disease.

9 May 2013 in Neuropsychopharmacology
Verified
Journal Article
Closed access
JFJennifer C Felger
Jennifer C Felger
JMJiyoung Mun
Jiyoung Mun
HKHeather Kimmel
Heather Kimmel
JNJonathon A Nye
Jonathon A Nye
DDDaniel F Drake
Daniel F Drake
AMAndrew H Miller
Andrew H Miller

1 January 2008 in Biochemical Pharmacology
Verified
Journal Article
Closed access
LHLeonard L. Howell
Leonard L. Howell
HKHeather Kimmel
Heather Kimmel

17 June 2017 in Tobacco Control
Verified
Journal Article
Closed access
PDF file
BCBlair N. Coleman
Blair N. Coleman
BRBrian Rostron
Brian Rostron
SJSarah E Johnson
Sarah E Johnson
BABridget K Ambrose
Bridget K Ambrose
JPJennifer Pearson
Jennifer Pearson
AHAndrew Hyland
Andrew Hyland
Background Electronic cigarette (e-cigarette) use in the USA is increasing. As such, it is critical to understand who uses e-cigarettes, how e-cigarettes are used and what types of products are prevalent. This study assesses patterns of current e-cigarette use among daily and non-daily adult users in the 2013–2014 Population Assessment of Tobacco and Health (PATH) Study. Methods We examined the proportion of current adult e-cigarette users (n=3642) reporting infrequent use (use on ‘some days’ and use on 0–2 of the past 30 days), moderate use (use on ‘some days’ and use on >2 of the past 30 days) and daily use. We examined demographic characteristics, use of other tobacco products and e-cigarette product characteristics overall and by use category. Adjusted prevalence ratios (aPRs) were calculated using Poisson regression to assess correlates of daily e-cigarette use. Results Among the 5.5% of adult current e-cigarette users in the PATH Study, 42.2% reported infrequent use, 36.5% reported moderate use and 21.3% reported daily use. Cigarette smokers who quit in the past year were more likely to report daily e-cigarette use, compared with current smokers (aPR=3.21, 95% CI=2.75 to 3.76). Those who reported using rechargeable or refillable devices were more likely to report daily use compared with those who did not use these devices (aPR=1.95, 95% CI=1.44 to 2.65 and aPR=2.10, 95% CI=1.75 to 2.52, respectively). Conclusions The majority of e-cigarette users in this study reported less than daily use. Compared with non-daily use, daily use was associated with being a former smoker; however, cross-sectional data limits our ability to establish the temporality or directionality of such associations.

1 August 2017 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
KCKevin Conway
Kevin Conway
VGVictoria R. Green
Victoria R. Green
KKKarin A. Kasza
Karin A. Kasza
MSMarushka L. Silveira
Marushka L. Silveira
NBNicolette Borek
Nicolette Borek
WCWilson M. Compton
Wilson M. Compton

1 September 2017 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
SSSuzaynn F. Francine Schick
Suzaynn F. Francine Schick
BBBenjamin C. Blount
Benjamin C. Blount
PJPeyton Jacob
Peyton Jacob
NSNajat Aoun Saliba
Najat Aoun Saliba
JBJohn T. Bernert
John T. Bernert
ABAruni Bhatnagar
Aruni Bhatnagar
Accurate and reliable measurements of exposure to tobacco products are essential for identifying and confirming patterns of tobacco product use and for assessing their potential biological effects in both human populations and experimental systems. Due to the introduction of new tobacco-derived products and the development of novel ways to modify and use conventional tobacco products, precise and specific assessments of exposure to tobacco are now more important than ever. Biomarkers that were developed and validated to measure exposure to cigarettes are being evaluated to assess their use for measuring exposure to these new products. Here, we review current methods for measuring exposure to new and emerging tobacco products, such as electronic cigarettes, little cigars, water pipes, and cigarillos. Rigorously validated biomarkers specific to these new products have not yet been identified. Here, we discuss the strengths and limitations of current approaches, including whether they provide reliable exposure estimates for new and emerging products. We provide specific guidance for choosing practical and economical biomarkers for different study designs and experimental conditions. Our goal is to help both new and experienced investigators measure exposure to tobacco products accurately and avoid common experimental errors. With the identification of the capacity gaps in biomarker research on new and emerging tobacco products, we hope to provide researchers, policymakers, and funding agencies with a clear action plan for conducting and promoting research on the patterns of use and health effects of these products.